U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C8H15NO2
Molecular Weight 157.2102
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXANAMIDE

SMILES

CCCC1OC1(CC)C(N)=O

InChI

InChIKey=WBLPIVIXQOFTPQ-UHFFFAOYSA-N
InChI=1S/C8H15NO2/c1-3-5-6-8(4-2,11-6)7(9)10/h6H,3-5H2,1-2H3,(H2,9,10)

HIDE SMILES / InChI
Molecular Formula C8H15NO2
Molecular Weight 157.2102
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Oxanamide is an anxiolytic and muscle relaxant that was effective in the treatment of anxiety resulting from premenstrual syndrome, menopause. The tranquilizing effect of oxanamide was noticeable within two or three days, and improvement in nervous and emotional symptoms was soon evident. Information about the current use of this drug is not available.

Approval Year

1958
129
Doses

Doses

DosePopulationAdverse events​
4.8 g multiple, oral
Highest studied dose
Dose: 4.8 g
Route: oral
Route: multiple
Dose: 4.8 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13638840
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/13638840
Sources:
https://pubmed.ncbi.nlm.nih.gov/13638840
800 mg 4 times / day multiple, oral
Studied dose
Dose: 800 mg, 4 times / day
Route: oral
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13638840
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/13638840
Sources:
https://pubmed.ncbi.nlm.nih.gov/13638840
Sourcing

Sourcing

Vendor/AggregatorIDURL
ABI Chem
AC1L1LHH
AHH Chemical co.,ltd
MR-1013859
http://www.ahhchemical.com/product/MR-1013859.html
Chemieliva Pharmaceutical Co., Ltd
PBCM0193178
Chemspace
CSC000076872
Enamine
BBV-38278618
LGC Standards
LGCFOR3211.00
https://www.lgcstandards.com/US/en/p/LGCFOR3211.00
MuseChem
M068883
NovoSeek
31365
Smolecule
S568982
https://www.smolecule.com/products/s568982
THE BioTek
bt-374734
https://www.thebiotek.com/product/others/bt-374734
ZINC
ZINC000000000571
http://zinc15.docking.org/substances/ZINC000000000571
ZINC
ZINC000002015517
http://zinc15.docking.org/substances/ZINC000002015517
ZINC
ZINC000002015518
http://zinc15.docking.org/substances/ZINC000002015518
ZINC
ZINC000002015519
http://zinc15.docking.org/substances/ZINC000002015519
PubMed

PubMed

TitleDatePubMed
Effects of oxanamide on anxiety during oral surgery.
1962-03
Effects of oxanamide on the central nervous system.
1960-01
Oxanamide; adjunctive use of a new tranquilizer in gynecology.
1959-04

Sample Use Guides

In Vivo Use Guide
dosage of three tablets daily (total 1,200 mg. oxanamide), the patients were instructed to reduce the dosage or to take the drug only at bedtime.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:19:43 GMT 2025
Edited
by admin
on Wed Apr 02 09:19:43 GMT 2025
Record UNII
050271194T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXANAMIDE
INN   MI  
INN  
Official Name English
OXANAMIDE [MI]
Preferred Name English
2,3-EPOXY-2-ETHYLHEXANAMIDE
Systematic Name English
oxanamide [INN]
Common Name English
Code System Code Type Description
DRUG CENTRAL
2010
Created by admin on Wed Apr 02 09:19:44 GMT 2025 , Edited by admin on Wed Apr 02 09:19:44 GMT 2025
PRIMARY
MERCK INDEX
m381
Created by admin on Wed Apr 02 09:19:43 GMT 2025 , Edited by admin on Wed Apr 02 09:19:43 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
OXANAMIDE
Created by admin on Wed Apr 02 09:19:43 GMT 2025 , Edited by admin on Wed Apr 02 09:19:43 GMT 2025
PRIMARY
EPA CompTox
DTXSID50925350
Created by admin on Wed Apr 02 09:19:44 GMT 2025 , Edited by admin on Wed Apr 02 09:19:44 GMT 2025
PRIMARY
ChEMBL
CHEMBL2105297
Created by admin on Wed Apr 02 09:19:43 GMT 2025 , Edited by admin on Wed Apr 02 09:19:43 GMT 2025
PRIMARY
EVMPD
SUB09495MIG
Created by admin on Wed Apr 02 09:19:43 GMT 2025 , Edited by admin on Wed Apr 02 09:19:43 GMT 2025
PRIMARY
CAS
126-93-2
Created by admin on Wed Apr 02 09:19:43 GMT 2025 , Edited by admin on Wed Apr 02 09:19:43 GMT 2025
PRIMARY
PUBCHEM
31365
Created by admin on Wed Apr 02 09:19:43 GMT 2025 , Edited by admin on Wed Apr 02 09:19:43 GMT 2025
PRIMARY
SMS_ID
100000083009
Created by admin on Wed Apr 02 09:19:44 GMT 2025 , Edited by admin on Wed Apr 02 09:19:44 GMT 2025
PRIMARY
FDA UNII
050271194T
Created by admin on Wed Apr 02 09:19:43 GMT 2025 , Edited by admin on Wed Apr 02 09:19:43 GMT 2025
PRIMARY
INN
812
Created by admin on Wed Apr 02 09:19:43 GMT 2025 , Edited by admin on Wed Apr 02 09:19:43 GMT 2025
PRIMARY
NCI_THESAURUS
C175181
Created by admin on Wed Apr 02 09:19:43 GMT 2025 , Edited by admin on Wed Apr 02 09:19:43 GMT 2025
PRIMARY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966